


THE LEINCO LATEST




We appreciate your continued support and are thrilled to share the latest updates and innovations from Leinco Technologies. In this edition, we bring you exciting news about our recent acquisition, newly launched products, and expanding capabilities. As always, our mission is to empower your research with reliable, high-quality reagents and services. We hope this newsletter helps keep you informed and inspired as we advance the world of life science together!

QED BIOSCIENCES ACQUISITION

We are excited to announce the acquisition of QED Biosciences, a leader in antibody and reagent development services. This strategic move strengthens our commitment to providing top-tier products and solutions for the research and diagnostic communities. For you, this means expanded access to a broader portfolio of high-quality antibodies, recombinant proteins, and reagents. By combining Leinco's innovation and QED's legacy of excellence, we're better equipped to support your research goals and provide cutting-edge tools for diagnostics and discovery.

Our expanded catalog and capabilities will deliver even greater value, offering new opportunities for custom antibody development, along with enhanced service offerings. We remain dedicated to providing exceptional quality, reliability, and customer service as we integrate QED's offerings into our portfolio. Stay tuned for even more innovative solutions to come!



READ
PRESS RELEASE

NEW BIOSIMILAR CLONES AVAILABLE NOW

At Leinco, we are constantly growing our biosimilar portfolio to meet the increasing demand for research-grade solutions. Since the start of this year, we've added over **29 new** biosimilar antibodies to our catalog, with **55 more** on the way. These high-quality, cost-effective biosimilars are ideal for humanized mouse models and other pre-clinical research, offering the same variable region sequences as therapeutic counterparts—without the high costs.



EXPLORE
BIOSIMILARS!

NEW INFECTIOUS DISEASE ANTIBODIES & ANTIGENS

We're excited to introduce new additions to our infectious disease antibody and reagent portfolio. These recombinant human monoclonal antibodies are designed to accelerate research into emerging diseases, supporting faster diagnostic development and therapeutic advancements. With the rise of infectious diseases, these antibodies provide essential tools for cutting-edge research.


Want to learn more about these cutting-edge products? Scan the QR code to access our new monograph



READ
MONOGRAPH!


DIGITAL NEWSLETTER

Help us save paper by signing up to receive these newsletters directly in your inbox! Opt-in using the QR code.



TALK TO AN EXPERT

Do you have specific product related questions? Are you needing more information about our custom services? Scan the QR code to contact our sales team directly, and they'll be sure to respond in a timely manner.



FOLLOW US

Stay up to date with everything that's going on at Leinco by following our social media accounts. You'll be the first to know about new products, promotions and so much more! Scan to follow.

